Eli Lilly's Trulicity Benefits From Growth of Diabetes Drugs
"We are benefiting from very significant growth of the GLP-1 class," said Conterno, president of Lilly Diabetes and Lilly USA, at the UBS Global Healthcare Conference in New York. "And in fact, as we see additional competitors, they are further fueling ...
Arnold & Porter Adds Ex-Sen. Dodd, Eli Lilly Litigation Chief
It was a busy day on the hiring front for Arnold & Porter Kaye Scholer, which said Tuesday that it had added Christopher Dodd, the former U.S. senator from Connecticut, and Steve Benz, who was head of litigation for pharmaceutical company Eli Lilly.
Eli Lilly posts quarterly loss, to take animal health unit public
Eli Lilly posted a second-quarter loss on Tuesday, hurt by acquisition-related charges of $1.62 billion. Continue Reading Below. The company incurred a net loss of $259.9 million, or 25 cents per share, in the second quarter, compared with a profit of ...
